neuroscience

Brain and nervous-system diseases such as Parkinson's, Alzheimer's and schizophrenia: drugs, devices and research for them.

Theme · 11 companies · 1 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“AbbVie’s neuroscience products address some of the most difficult-to-treat neurologic diseases.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ADRX ADARx Pharmaceuticals, Inc.

    In development“Our neuron-targeted program, ADX-199, is designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • ASPE Aspen Neuroscience, Inc.

    In development“Our lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of PD.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • BMY Bristol-Myers Squibb

    Sells it <1%, $155.0M a year“Cobenfy (xanomeline and trospium chloride) is an oral combination of xanomeline, a M1/M4 muscarinic agonist, and trospium chloride, a peripheral muscarinic antagonist, indicated for the treatment of schizophrenia in adults.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • CTY CITY THERAPEUTICS, INC.

    Supplies it“In May 2025, we established a strategic collaboration with Biogen that combines our RNAi trigger technology with Biogen’s proprietary drug delivery technology to develop a novel systemic therapy for the treatment of certain CNS diseases.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • IAM Iambic Therapeutics, Inc.

    Supplies it“Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer demonstrate meaningful external interest in our platform, and are expanding the impact of our platform to additional target classes (for example, G protein-coupled receptors), additional therapeutic indications (for example, neurology, gastrointestinal, inflammation and immunology), and additional small-molecule mechanisms of action (for example, molecular glues, and glue degraders).”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • JNJ Johnson & Johnson

    Sells it“Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia)”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • MDT Medtronic

    Sells it“Neuroscience growth reflected AiBLE adoption, Altaviva, ENT, Neurovascular, Pain Stim and Percept RC, partly offset by the Pipeline Vantage recall.”

    Latest 8-KPositiveDeal completedLeadership changeExecutive pay ·

    MiniMed separation completed after the exchange offer was 5.4x subscribed.

  • RZRA Rezera Inc.

    In development“Our development plan for trabzanoflast will focus on neuroinflammatory indications.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SCTX Scribe Therapeutics, Inc.

    Supplies it“In our collaboration with Lilly, we combine our CRISPR by Design approach with Lilly’s expertise in the development of genetic medicines for neurological and neuromuscular disorders.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • SDGR Schrödinger, Inc.

    Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%

Feedback